147 related articles for article (PubMed ID: 37868533)
1. Ras Association Domain Family 1A Gene Promoter Methylation as a Biomarker for Chronic Viral Hepatitis C-related Hepatocellular Carcinoma.
Abou Zeid AA; El-Sayed ET; Ahdy JK; Tawfik MR
Cureus; 2023 Sep; 15(9):e45687. PubMed ID: 37868533
[TBL] [Abstract][Full Text] [Related]
2. Association of RASSF1A hypermethylation with risk of HBV/HCV-induced hepatocellular carcinoma: A meta-analysis.
Peng JL; Wu JZ; Li GJ; Wu JL; Xi YM; Li XQ; Wang L
Pathol Res Pract; 2020 Oct; 216(10):153099. PubMed ID: 32853942
[TBL] [Abstract][Full Text] [Related]
3. Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C?
Mohamed NA; Swify EM; Amin NF; Soliman MM; Tag-Eldin LM; Elsherbiny NM
Arab J Gastroenterol; 2012 Sep; 13(3):111-5. PubMed ID: 23122451
[TBL] [Abstract][Full Text] [Related]
4. Combination of serum RASSF1A methylation and AFP is a promising non-invasive biomarker for HCC patient with chronic HBV infection.
Dong X; He H; Zhang W; Yu D; Wang X; Chen Y
Diagn Pathol; 2015 Aug; 10():133. PubMed ID: 26238200
[TBL] [Abstract][Full Text] [Related]
5. Methylation of tumour suppressor genes
El-Bendary M; Nour D; Arafa M; Neamatallah M
Br J Biomed Sci; 2020 Jan; 77(1):35-40. PubMed ID: 31790342
[No Abstract] [Full Text] [Related]
6. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma.
Schagdarsurengin U; Wilkens L; Steinemann D; Flemming P; Kreipe HH; Pfeifer GP; Schlegelberger B; Dammann R
Oncogene; 2003 Mar; 22(12):1866-71. PubMed ID: 12660822
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of
Nomeir H; Elsheredy H; Nomeir A; Mostafa NR; El-Hamshary S
Clin Exp Hepatol; 2022 Sep; 8(3):243-252. PubMed ID: 36685264
[TBL] [Abstract][Full Text] [Related]
8. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA.
Zhang YJ; Wu HC; Shen J; Ahsan H; Tsai WY; Yang HI; Wang LY; Chen SY; Chen CJ; Santella RM
Clin Cancer Res; 2007 Apr; 13(8):2378-84. PubMed ID: 17438096
[TBL] [Abstract][Full Text] [Related]
9. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma.
Chan KC; Lai PB; Mok TS; Chan HL; Ding C; Yeung SW; Lo YM
Clin Chem; 2008 Sep; 54(9):1528-36. PubMed ID: 18653827
[TBL] [Abstract][Full Text] [Related]
10. Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver.
Di Gioia S; Bianchi P; Destro A; Grizzi F; Malesci A; Laghi L; Levrero M; Morabito A; Roncalli M
BMC Cancer; 2006 Apr; 6():89. PubMed ID: 16606445
[TBL] [Abstract][Full Text] [Related]
11. RASSF1A methylation as a biomarker for detection of colorectal cancer and hepatocellular carcinoma.
Li J; Li H; Run ZC; Wang ZL; Jiang T; An Y; Li Z
World J Gastrointest Oncol; 2022 Aug; 14(8):1574-1584. PubMed ID: 36160746
[TBL] [Abstract][Full Text] [Related]
12. The Association of Ala133Ser Polymorphism and Methylation in Ras Association Domain Family 1A Gene With Unfavorable Prognosis of Hepatocellular Carcinoma.
Feng Y; Li P; Liu Y; Sha Z; Feng L; Wang F; Mao Q; Xue W
Hepat Mon; 2015 Oct; 15(10):e32145. PubMed ID: 26587041
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma.
Hu L; Chen G; Yu H; Qiu X
Hepatol Int; 2010 Jan; 4(1):423-32. PubMed ID: 20305761
[TBL] [Abstract][Full Text] [Related]
14. Identification of RASSF1A promoter hypermethylation as a biomarker for hepatocellular carcinoma.
Xu G; Zhou X; Xing J; Xiao Y; Jin B; Sun L; Yang H; Du S; Xu H; Mao Y
Cancer Cell Int; 2020 Nov; 20(1):547. PubMed ID: 33292241
[TBL] [Abstract][Full Text] [Related]
15. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas.
Zhong S; Yeo W; Tang MW; Wong N; Lai PB; Johnson PJ
Clin Cancer Res; 2003 Aug; 9(9):3376-82. PubMed ID: 12960125
[TBL] [Abstract][Full Text] [Related]
16. Differential methylation of the promoter and first exon of the RASSF1A gene in hepatocarcinogenesis.
Jain S; Xie L; Boldbaatar B; Lin SY; Hamilton JP; Meltzer SJ; Chen SH; Hu CT; Block TM; Song W; Su YH
Hepatol Res; 2015 Nov; 45(11):1110-23. PubMed ID: 25382672
[TBL] [Abstract][Full Text] [Related]
17. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma.
Yeo W; Wong N; Wong WL; Lai PB; Zhong S; Johnson PJ
Liver Int; 2005 Apr; 25(2):266-72. PubMed ID: 15780049
[TBL] [Abstract][Full Text] [Related]
18. RASSF1A and DOK1 Promoter Methylation Levels in Hepatocellular Carcinoma, Cirrhotic and Non-Cirrhotic Liver, and Correlation with Liver Cancer in Brazilian Patients.
Araújo OC; Rosa AS; Fernandes A; Niel C; Villela-Nogueira CA; Pannain V; Araujo NM
PLoS One; 2016; 11(4):e0153796. PubMed ID: 27078152
[TBL] [Abstract][Full Text] [Related]
19. Circulating Hypermethylated RASSF1A as a Molecular Biomarker for Diagnosis of Hepatocellular Carcinoma.
Mansour LA; El Raziky M; Mohamed AA; Mahmoud EH; Hamdy S; El Sayed EH
Asian Pac J Cancer Prev; 2017 Jun; 18(6):1637-1643. PubMed ID: 28670882
[TBL] [Abstract][Full Text] [Related]
20. RASSF1A and SOCS1 genes methylation status as a noninvasive marker for hepatocellular carcinoma.
Pasha HF; Mohamed RH; Radwan MI
Cancer Biomark; 2019; 24(2):241-247. PubMed ID: 30689554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
